Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Hepatology (Baltimore, Md.)
|
May 4, 2004
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis
Shuji Matsumura, Judy Van De Water, Patrick Leung, et al.
Digestive Diseases and Sciences
|
July 11, 2013
Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates
Aftab Ala, David Brown, Korsa Khan, et al.
The American Journal of Gastroenterology
|
April 22, 2005
Evaluation of fatigue in U.S. patients with primary biliary cirrhosis
Carmen M Stanca, Nancy Bach, Cynthia Krause, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 15, 2013
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
James F Crismale, Valérie Martel-Laferrière, Kian Bichoupan, et al.
Journal of Autoimmunity
|
January 16, 2007
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis
Jorge Allina, Bin Hu, Daniel M Sullivan, et al.
Alimentary Pharmacology & Therapeutics
|
July 11, 2024
Clinical characteristics and HLA associations of azithromycin-induced liver injury
Caroline Conlon, Yi-Ju Li, Jawad Ahmad, et al.
Inflammatory Bowel Diseases
|
January 26, 2013
Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia
Joana Torres, Xiuliang Bao, Alina C Iuga, et al.
Hepatology (Baltimore, Md.)
|
July 29, 2014
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response
Kian Bichoupan, Valerie Martel-Laferriere, David Sachs, et al.
World Journal of Hepatology
|
May 5, 2017
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
Kian Bichoupan, Neeta Tandon, Valerie Martel-Laferriere, et al.
Gastroenterology
|
December 10, 2022
Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate
Paola Nicoletti, Andrew Dellinger, Yi Ju Li, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Hepatology (Baltimore, Md.)
|
May 4, 2004
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis
Shuji Matsumura, Judy Van De Water, Patrick Leung, et al.
Digestive Diseases and Sciences
|
July 11, 2013
Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates
Aftab Ala, David Brown, Korsa Khan, et al.
The American Journal of Gastroenterology
|
April 22, 2005
Evaluation of fatigue in U.S. patients with primary biliary cirrhosis
Carmen M Stanca, Nancy Bach, Cynthia Krause, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 15, 2013
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
James F Crismale, Valérie Martel-Laferrière, Kian Bichoupan, et al.
Journal of Autoimmunity
|
January 16, 2007
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis
Jorge Allina, Bin Hu, Daniel M Sullivan, et al.
Alimentary Pharmacology & Therapeutics
|
July 11, 2024
Clinical characteristics and HLA associations of azithromycin-induced liver injury
Caroline Conlon, Yi-Ju Li, Jawad Ahmad, et al.
Inflammatory Bowel Diseases
|
January 26, 2013
Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia
Joana Torres, Xiuliang Bao, Alina C Iuga, et al.
Hepatology (Baltimore, Md.)
|
July 29, 2014
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response
Kian Bichoupan, Valerie Martel-Laferriere, David Sachs, et al.
World Journal of Hepatology
|
May 5, 2017
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
Kian Bichoupan, Neeta Tandon, Valerie Martel-Laferriere, et al.
Gastroenterology
|
December 10, 2022
Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate
Paola Nicoletti, Andrew Dellinger, Yi Ju Li, et al.
Page
of 5